Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name (Descending) Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00093-7664-56 00093-7664 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 In Use
62856-0389-01 62856-0389 Eribulin mesylate Halaven 0.5 mg/mL Chemotherapy Antimitotic Agent Furopyrans Intravenous Nov. 15, 2010 In Use
59676-0040-28 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0040-56 59676-0040 Erdafitinib BALVERSA 4.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0050-28 59676-0050 Erdafitinib BALVERSA 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-56 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59676-0030-84 59676-0030 Erdafitinib BALVERSA 3.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Oral April 12, 2019 In Use
59353-0002-10 59353-0002 Epoetin alfa-epbx RETACRIT 2000.0 [iU]/mL, 2000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
59353-0003-10 59353-0003 Epoetin alfa-epbx RETACRIT 3000.0 [iU]/mL, 3000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use
59353-0004-10 59353-0004 Epoetin alfa-epbx RETACRIT 4000.0 [iU]/mL, 4000.0 [iU]/mL Ancillary Therapy Erythropoiesis-Stimulating Agent Intravenous, Subcutaneous June 18, 2018 In Use

Found 10,000 results in 8 milliseconds — Export these results